Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS(®) System to Firefly’s nationwide network of Evoke™ clinicians –

– Collaboration brings together an FDA-cleared pediatric ADHD treatment and Firefly’s objective brain-function assessment platform and AI-driven ADHD biomarker research –